Mortality in schizophrenia

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 12, 2007, Pages 1308-1312

  Auquier, Pascal ^a   Lançon, Christophe ^b   Rouillon, Frédéric ^c   Lader, Malcolm ^d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Laboratoire Central   (France)

^c Hopital Albert Chenevier   (France)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Cardiovascular deaths; Mortality; Respiratory deaths; Schizophrenia; Suicide

Indexed keywords

CLOZAPINE; GLUCOSE; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; THIORIDAZINE; THIOXANTHENE DERIVATIVE;

ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMORBIDITY; DIET THERAPY; DISEASE ASSOCIATION; DYSLIPIDEMIA; EXERCISE; GLUCOSE BLOOD LEVEL; HEART DEATH; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; SUICIDE; THERAPY DELAY; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; HUMANS; MALE; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; SUICIDE; SURVIVAL RATE;

EID: 37349110277     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1496     Document Type: Article

References (28)

1. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508.
2. Ösby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 2000; 45: 21-28.
3. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
4. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239-245.
5. Casadebaig F, Philippe A. Mortality in schizophrenia patients. 3 years follow-up of a cohort. Encephale 1999; 25(4): 329-337.
6. Mortensen PB, Juel K. Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 1990; 81: 372-377.
7. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. Br J Psychiatry 1997; 170: 205-228.
8. Baxter D, Appleby L. Case register study of suicide risk in mental disorders. Br J Psychiatry 1999; 175: 322-326.
9. Wilkinson G, Bacon NA. A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics. Psychol Med 1984; 14: 899-912.
10. Montout C, Casadebaig F, Lagnaoui R, et al. Neuroleptic and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res 2002; 57: 147-156.
11. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60(1): 82-91.
12. Smith J, Hucker S. Schizophrenia and substance abuse. Br J Psychiatry 1994; 165: 13-21.
13. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999; 46: 899-907.
14. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701.
15. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998; 6(Suppl. 2): 51S-63S.
16. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
17. Troiano RP, Frongillo EA, Jr, Sobal J, Levitsky DA. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord 1996; 20: 63-75.
18. Allison DB, Fontaine KR, Manson JE, et al. Annual death rates attributable to obesity in the United States. JAMA 1999; 282: 1530-1538.
19. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215-220.
20. Hutton J. The economics of treating obesity. Pharmacoeconomics 1994; 5: 66-72.
21. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214-217.
22. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996; 169: 733-739.
23. Stedman T, Welham J. The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br J Psychiatry 1993; 162: 249-250.
24. Centorrino F, Baldessarini RJ, Kando JC, et al. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994, 14: 119-125.
25. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
26. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161-1167.
27. British National Formulary. Vol. 48, September 2004. BMJ Publishing Group Ltd and RPS Publishing: London.
28. Lader M. Consensus statements on standards of care in schizophrenia. Prim Care Psychiatry 1997; 3: 145-149.